专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO03049717A2 CONDUCTANCE OF IMPROPERLY FOLDED PROTEINS THROUGH THE SECRETORY PATHWAY AND RELATED METHODS FOR TREATING DISEASE 审中-公开
标题翻译：通过秘密路径导致的不正确折叠蛋白质的导管及相关治疗疾病的方法
公开(公告)号：WO03049717A2
公开(公告)日：2003-06-19
申请号：PCT/US0232801
申请日：2002-10-15
申请人： PANACEA PHARM LLC , CAPLAN MICHAEL J , EGAN MARIE E
发明人： CAPLAN MICHAEL J , EGAN MARIE E
IPC分类号： A61K9/00 , A61K9/20 , A61K31/00 , A61K31/02 , A61K31/122 , A61K31/343 , A61K31/365 , A61K31/38 , A61K31/40 , A61K31/407 , A61K31/47 , A61K31/713 , A61K38/16 , A61P5/48 , A61P7/00 , A61P11/00 , A61P13/00 , A61P31/12 , A61P35/00 , A61P43/00 , C12Q1/48 , G01N33/50 , A61K9/12 , A61K48/00
CPC分类号： A61K9/0078 , A61K9/0031 , A61K9/0053 , A61K9/0073 , A61K9/2013 , A61K9/2022 , A61K31/00 , A61K31/02 , A61K31/122 , A61K31/343 , A61K31/365 , A61K31/38 , A61K31/40 , A61K31/407 , A61K31/47 , A61K31/55 , A61K31/713 , C12Q1/48 , G01N33/5008 , G01N33/502 , G01N33/5044 , G01N33/5076 , G01N33/6872 , G01N2333/91102
摘要： This invention provides the methodology and agents for treating any disease or clinical condition which is at least partly the result of endoplasmic reticulum-associated retention of proteins. Thus, the methods and agents of the present invention provide for the release of normally retained proteins from the endoplasmic reticulum. The present invention is particularly useful for treating any disease or clinical condition which is at least partly the result of endoplasmic reticulum-associated retention or degradation of mis-assembled or mis-folded proteins.
摘要翻译：本发明提供用于治疗任何疾病或临床病症的方法和试剂，其至少部分是蛋白质内质网相关保留的结果。因此，本发明的方法和试剂提供从内质网释放正常保留的蛋白质。本发明特别可用于治疗至少部分由内质网相关的残留或错误组合或错误折叠的蛋白质降解的结果的疾病或临床病症。

2. 发明申请

WO0140264A9 PEPTIDE ANTIGENS 审中-公开
标题翻译：肽抗原
公开(公告)号：WO0140264A9
公开(公告)日：2002-05-30
申请号：PCT/US0033124
申请日：2000-12-06
申请人： PANACEA PHARM LLC , UNIV ARKANSAS , SINAI SCHOOL MEDICINE
发明人： BANNON GARY A , BURKS WESLEY A , CAPLAN MICHAEL J , SAMPSON HUGH , SOSIN HOWARD
IPC分类号： A01K67/027 , A61K38/11 , A61K39/00 , A61K39/35 , A61K39/36 , A61K39/38 , C07K14/415 , A01K67/02 , C07K7/08 , G01N33/68
CPC分类号： C07K14/415 , A01K67/027 , A61K38/00 , A61K39/00 , A61K39/35 , A61K39/36 , A61K39/38 , A61K2039/53
摘要： The present invention provides compositions and methods for reducing the severity and/or number of allergic symptoms in individuals sensitive to one or more antigens. In general, the inventive compositions comprise fragments of antigens and are characterized by a reduced ability to bind to anti-antigen IgE. Preferred compositions comprise overlapping fragments that together represent substantially all of the structural features of the relevant antigen except that one or more IgE binding sites may be omitted. Particularly preferred compositions comprise fragments of anaphylactic antigens, especially food antigens such as peanut antigens or shellfish antigens.
摘要翻译：本发明提供用于降低对一种或多种抗原敏感的个体的过敏症状的严重性和/或数量的组合物和方法。通常，本发明的组合物包含抗原片段，其特征在于与抗原IgE结合的能力降低。优选的组合物包含重叠的片段，其一起代表相关抗原的基本上所有的结构特征，除了可以省略一个或多个IgE结合位点。特别优选的组合物包含过敏抗原的片段，特别是食品抗原如花生抗原或贝类抗原。

3. 发明申请

WO0139799A9 PASSIVE DESENSITIZATION 审中-公开
标题翻译：被动的诽谤
公开(公告)号：WO0139799A9
公开(公告)日：2002-05-30
申请号：PCT/US0033125
申请日：2000-12-06
申请人： PANACEA PHARM LLC
发明人： CAPLAN MICHAEL
IPC分类号： A01K67/027 , A61K38/11 , A61K39/00 , A61K39/35 , A61K39/36 , A61K39/38 , C07K14/415 , A61K39/385 , A61K39/395
CPC分类号： C07K14/415 , A01K67/027 , A61K38/00 , A61K39/00 , A61K39/35 , A61K39/36 , A61K39/38 , A61K2039/53
摘要： IgE-blocking agents and methods of their use have been developed for desensitizing an individual to an antigen. These IgE-blocking agents work by blocking the antigen-binding site of the IgE molecules and thereby preventing the antigen from binding. These agents typically have up to one IgE binding site present per molecule so as to prevent any cross-linking of IgE which could lead to an allergic reaction. Methods of using these novel IgE blocking agents include administering the agents to alleviate or prevent allergic reactions as well as administering the agents to decrease the risk of allergic reactions during immunotherapy or "rush" immunotherapy. Compositions and kits comprising these IgE binding agents are also provided.
摘要翻译：已经开发了IgE阻断剂及其使用方法以使个体对抗原脱敏。这些IgE阻断剂通过阻断IgE分子的抗原结合位点并由此阻止抗原结合起作用。这些试剂通常在每个分子中具有多达一个IgE结合位点，以防止可能导致过敏反应的IgE的任何交联。使用这些新的IgE阻断剂的方法包括施用所述药剂以缓解或预防过敏反应，以及施用所述药剂以降低免疫疗法或“抢”免疫疗法期间的过敏反应的风险。还提供了包含这些IgE结合剂的组合物和试剂盒。

4. 发明申请

WO0166136A2 MICROBIAL DELIVERY SYSTEM 审中-公开
标题翻译：微生物递送系统
公开(公告)号：WO0166136A2
公开(公告)日：2001-09-13
申请号：PCT/US0033121
申请日：2000-12-06
申请人： PANACEA PHARM LLC
发明人： CAPLAN MICHAEL
IPC分类号： A61K39/02 , A61K39/00 , A61K39/002 , A61K39/12 , A61K39/35 , A61P37/08 , A61K35/66
CPC分类号： A61K39/35 , A61K2039/5156 , A61K2039/523 , A61K2039/5256
摘要： The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies. Methods of the present invention utilize administration of microorganisms to subjects, where the microorganisms produce allergens and protect the subjects from exposure to the allergens until phagocytosed by antigen-presenting cells. Particularly preferred microorganisms are gram-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex that elicit allergic reactions and anaphylactic allergic reactions in individuals who are allergic to the proteins or are susceptible to allergies to the proteins. The proteins may also be modified to reduce the ability of the proteins to bind and crosslink IgE antibodies and thereby reduce the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity.
摘要翻译：本发明提供了用于治疗或预防对过敏原过敏或对过敏敏感的受试者的过敏反应，特别是过敏性过敏反应的方法和组合物。本发明的方法利用向受试者施用微生物，其中微生物产生过敏原并保护受试者免于暴露于过敏原直至被抗原呈递细胞吞噬。特别优选的微生物是革兰氏阴性菌，革兰氏阳性菌和酵母。特别优选的过敏原是在对蛋白质过敏或对蛋白质过敏敏感的个体中引起过敏反应和过敏性过敏反应的食物，毒液，药物和乳胶中发现的蛋白质。蛋白质也可以被修饰以降低蛋白质结合和交联IgE抗体的能力，从而降低引发过敏反应而不影响T细胞介导的Th1型免疫的风险。

5. 发明申请

WO0054803A3 IMMUNOSTIMULATORY NUCLEIC ACIDS AND ANTIGENS 审中-公开
标题翻译：免疫细胞核酸和抗原
公开(公告)号：WO0054803A3
公开(公告)日：2001-01-11
申请号：PCT/US0007213
申请日：2000-03-16
申请人： PANACEA PHARM LLC
发明人： SOSIN HOWARD B , CAPLAN MICHAEL J
IPC分类号： A61K39/35 , A61K39/38 , A61K39/39 , A61P37/04 , A61P37/08
CPC分类号： A61K39/38 , A61K39/35 , A61K39/39 , A61K2039/55561
摘要： The present invention provides methods and compositions for modulating an individual's immune response to antigens. It is an aspect of the present invention that allergic responses to antigens, which in some cases lead to asthma and even anaphylaxis, can be treated or prevented by administering compositions having immunostimulatory oligonucleotides having unmethylated CpG sequences. It is another aspect of the present invention that allergies to antigens, especially one that result in asthma and anaphylaxis, can be treated or prevented by administering compositions containing immunostimulatory oligonucleotides having unmethylated CpG dinucleotide sequences and further comprising antigen(s), fragments of the antigen, mixtures of fragments of the antigen, antigens modified to reduce Th2-type immune responses, and fragments of the antigen modified to reduce Th2-type immune responses. Cellular systems for studying immunostimulation by CpG containing nucleic acids include in vivo, in vitro or ex vivo systems.
摘要翻译：本发明提供了调节个体对抗原的免疫应答的方法和组合物。本发明的一个方面是通过施用具有具有非甲基化CpG序列的免疫刺激性寡核苷酸的组合物来治疗或预防对某些情况下导致哮喘甚至过敏反应的抗原的过敏反应。本发明的另一方面是通过施用含有具有非甲基化CpG二核苷酸序列的免疫刺激性寡核苷酸的组合物，并且进一步包含抗原，抗原片段，可以治疗或预防抗原，特别是导致哮喘和过敏反应的抗原，抗原片段的混合物，被修饰以减少Th2型免疫应答的抗原，以及被修饰以减少Th2型免疫应答的抗原片段。用于研究含有CpG的核酸的免疫刺激的细胞系统包括体内，体外或离体系统。

6. 发明申请

WO0140264A2 PEPTIDE ANTIGENS 审中-公开
标题翻译：肽抗原
公开(公告)号：WO0140264A2
公开(公告)日：2001-06-07
申请号：PCT/US0033124
申请日：2000-12-06
申请人： PANACEA PHARM LLC , UNIV ARKANSAS , SINAI SCHOOL MEDICINE
发明人： BANNON GARY A , BURKS WESLEY A , CAPLAN MICHAEL J , SAMPSON HUGH , SOSIN HOWARD
IPC分类号： A01K67/027 , A61K38/11 , A61K39/00 , A61K39/35 , A61K39/36 , A61K39/38 , C07K14/415 , C07K7/00
CPC分类号： C07K14/415 , A01K67/027 , A61K38/00 , A61K39/00 , A61K39/35 , A61K39/36 , A61K39/38 , A61K2039/53
摘要： The present invention provides compositions and methods for reducing the severity and/or number of allergic symptoms in individuals sensitive to one or more antigens. In general, the inventive compositions comprise fragments of antigens and are characterized by a reduced ability to bind to anti-antigen IgE. Preferred compositions comprise overlapping fragments that together represent substantially all of the structural features of the relevant antigen except that one or more IgE binding sites may be omitted. Particularly preferred compositions comprise fragments of anaphylactic antigens, especially food antigens such as peanut antigens or shellfish antigens.
摘要翻译：本发明提供用于降低对一种或多种抗原敏感的个体的过敏症状的严重性和/或数量的组合物和方法。通常，本发明的组合物包含抗原片段，其特征在于与抗原IgE结合的能力降低。优选的组合物包含重叠的片段，其一起代表相关抗原的基本上所有的结构特征，除了可以省略一个或多个IgE结合位点。特别优选的组合物包含过敏抗原的片段，特别是食品抗原如花生抗原或贝类抗原。

7. 发明申请

WO0139799A2 PASSIVE DESENSITIZATION 审中-公开
标题翻译：被动解析
公开(公告)号：WO0139799A2
公开(公告)日：2001-06-07
申请号：PCT/US0033125
申请日：2000-12-06
申请人： PANACEA PHARM LLC
发明人： CAPLAN MICHAEL
IPC分类号： A01K67/027 , A61K38/11 , A61K39/00 , A61K39/35 , A61K39/36 , A61K39/38 , C07K14/415
CPC分类号： C07K14/415 , A01K67/027 , A61K38/00 , A61K39/00 , A61K39/35 , A61K39/36 , A61K39/38 , A61K2039/53
摘要： IgE-blocking agents and methods of their use have been developed for desensitizing an individual to an antigen. These IgE-blocking agents work by blocking the antigen-binding site of the IgE molecules and thereby preventing the antigen from binding. These agents typically have up to one IgE binding site present per molecule so as to prevent any cross-linking of IgE which could lead to an allergic reaction. Methods of using these novel IgE blocking agents include administering the agents to alleviate or prevent allergic reactions as well as administering the agents to decrease the risk of allergic reactions during immunotherapy or "rush" immunotherapy. Compositions and kits comprising these IgE binding agents are also provided.
摘要翻译：已经开发了IgE阻断剂及其使用方法，用于使个体对抗原脱敏。这些IgE阻断剂通过阻断IgE分子的抗原结合位点起作用，从而防止抗原结合。这些药剂通常每分子存在多达一个IgE结合位点，以便防止可导致过敏反应的IgE的任何交联。使用这些新颖的IgE阻断剂的方法包括施用该药物以减轻或预防过敏反应，以及施用该药物以降低免疫治疗或“急性”免疫治疗期间过敏反应的风险。还提供了包含这些IgE结合剂的组合物和试剂盒。

8. 发明申请

WO0047610A3 METHOD FOR ALTERING UNDESIRABLE IMMUNE RESPONSES TO POLYPEPTIDES 审中-公开
标题翻译：改变对多肽的不可预见的免疫应答的方法
公开(公告)号：WO0047610A3
公开(公告)日：2000-11-30
申请号：PCT/US0003448
申请日：2000-02-10
申请人： PANACEA PHARM LLC
发明人： CAPLAN MICHAEL
IPC分类号： A01H5/00 , A01K67/027 , A61K38/00 , A61K45/00 , A61P37/02 , C07K14/435 , C07K19/00 , C12N15/01 , C12N15/09 , G01N33/15 , G01N33/50 , G01N33/53 , G01N33/68 , G01N37/00 , A61K39/35 , C07K14/00 , C12N15/82
CPC分类号： G01N33/6878
摘要： The disclosed method involves providing a collection of mutant polypeptides where the amino acid sequence of each mutant polypeptide differs in at least one position from a polypeptide of interest, identifying mutant polypeptides that exhibit less of the immune response than the polypeptide of interest, and identifying mutant polypeptides with less potential for eliciting an undesirable immune response that still retain the desired characteristic(s). The collection of mutant polypeptides can be provided by mutagenizing nucleic acid encoding a polypeptide of interest and expressing the mutagenized nucleic acid to produce mutant polypeptides. The method is especially useful for reducing immune responses involving both linear and/or conformational epitopes on a polypeptide of interest. This is possible because the recombinant polypeptides used as substrates for mutagenesis in the method are essentially full length, remaining structurally similar to the polypeptide of interest and displaying essentially the same conformational epitopes.
摘要翻译：所公开的方法包括提供突变体多肽的集合，其中每个突变体多肽的氨基酸序列在与感兴趣的多肽至少一个位置上不同，鉴定显示比感兴趣的多肽少的免疫应答的突变体多肽，以及鉴定突变体具有较小可能性的多肽引发仍然保留所需特征的不良免疫应答。可以通过诱变编码感兴趣多肽的核酸并表达诱变的核酸以产生突变多肽来提供突变多肽的集合。该方法对于减少涉及目的多肽上的线性和/或构象表位的免疫应答特别有用。这是可能的，因为在该方法中用作诱变的底物的重组多肽基本上是全长的，保持结构上类似于目的多肽并显示基本上相同的构象表位。

9. 发明申请

WO0139800A3 CONTROLLED DELIVERY OF ANTIGENS 审中-公开
标题翻译：控制输送抗原
公开(公告)号：WO0139800A3
公开(公告)日：2001-12-13
申请号：PCT/US0042607
申请日：2000-12-06
申请人： UNIV ARKANSAS , PANACEA PHARM LLC
发明人： CAPLAN MICHAEL , BURKS WESLEY A JR , BANNON GARY A
IPC分类号： A61K9/00 , A61K9/16 , A61K39/35 , A61P37/02 , A61K39/00 , A61K9/127 , A61K47/48 , A61P37/00
CPC分类号： A61K9/1647 , A61K39/35 , A61K2039/541 , A61K2039/57 , A61K2039/6093
摘要： Formulations and methods have been developed for delivering antigens to individuals in a manner that substantially reduces contact between the antigen and IgE receptors displayed on the surfaces of cells involved in mediating allergic responses. By reducing direct and indirect association of antigens with antigen-specific IgE antibodies, the risk of an allergic reaction, possibly anaphylatic shock, is reduced or eliminated. In the preferred embodiments, the compositions include one or more antigens in a delivery material such as a polymer, in the form of particles or a gel, or lipid vesicles or liposomes, any of which can be stabilized or targeted to enhance delivery. Preferably, the antigen is surrounded by the encapsulation materiel. One result of encapsulating antigen is the reduction in association with antigen-specific IgE antibodies. In a preferred embodiment, the formulation is designed to deliver antigens to individuals in a manner designed to promote a Th1-type mediated immune response and/or in a manner designed to suppress a Th2 response. In still another embodiment, the formulation effects preferential release of the antigen within APCs.
摘要翻译：已经开发出制剂和方法，用于以显着降低参与介导过敏反应的细胞表面上显示的抗原与IgE受体之间的接触的方式将抗原递送给个体。通过减少抗原与抗原特异性IgE抗体的直接和间接结合，减少或消除过敏反应（可能是过敏性休克）的风险。在优选的实施方案中，组合物包括递送材料中的一种或多种抗原，例如以颗粒或凝胶形式的聚合物，或脂质囊泡或脂质体，其中任一种可以被稳定或靶向以增强递送。优选地，抗原被包封材料包围。包封抗原的一个结果是与抗原特异性IgE抗体相关的减少。在优选的实施方案中，所述制剂被设计为以设计用于促进Th1型介导的免疫应答和/或以设计为抑制Th2应答的方式将抗原递送给个体。在另一个实施方案中，所述制剂会影响抗原在APC内的优先释放。

10. 发明申请

WO0037067A3 SENSITIZING AGENTS FOR THE TREATMENT OF SKIN LESIONS 审中-公开
标题翻译：用于治疗皮肤损伤的敏感剂
公开(公告)号：WO0037067A3
公开(公告)日：2001-01-18
申请号：PCT/US9930875
申请日：1999-12-22
申请人： PANACEA PHARM LLC , GOLDBERG HARRY , SAMPSON HUGH , SOSIN HOWARD B
发明人： GOLDBERG HARRY , SAMPSON HUGH , SOSIN HOWARD B
IPC分类号： A61K9/70 , A61K31/05 , A61K31/711 , A61K31/715 , A61K31/739 , A61K36/18 , A61K36/22 , A61K38/19 , A61K38/22 , A61K39/00 , A61K39/02 , A61K39/10 , A61K39/106 , A61K39/39 , A61K45/00 , A61P17/00 , A61P17/02 , A61P35/00 , A61P37/02 , A61P37/08 , A61K35/78
CPC分类号： A61K36/22 , A61K2300/00
摘要： The present invention provides compositions and methods for treating skin lesions by contacting the lesion with a sensitizing agent capable of eliciting a local immune response in the individual suffering from the lesion. The inventive compositions and methods may be applied in pharmaceutical and/or veterinary contexts.
摘要翻译：本发明提供了通过使损伤与能够在患有病变的个体中引起局部免疫应答的敏化剂接触来治疗皮肤损伤的组合物和方法。本发明的组合物和方法可以应用于药物和/或兽医学上下文中。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式